Gut microbiome as a treatment in colorectal cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Costello EK, Lauber CL, Hamady M, et al. Bacterial community variation in human body habitats across space and time. Science. 2009;326(5960):1694–1697. doi:10.1126/science.1177486.
   PubMed Web of Science ®Google Scholar
• Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–1836. doi:10.1042/BCJ20160510.
   PubMed Web of Science ®Google Scholar
• Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489(7415):242–249. doi:10.1038/nature11552.
   PubMed Web of Science ®Google Scholar
• Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015;31(1):69–75. doi:10.1097/MOG.0000000000000139.
   PubMed Web of Science ®Google Scholar
• Busnelli M, Manzini S, Chiesa G. The gut microbiota affects host pathophysiology as an endocrine organ: a focus on cardiovascular disease. Nutrients. 2019;12(1):79. doi:10.3390/nu12010079.
   PubMed Web of Science ®Google Scholar
• Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55–71. doi:10.1038/s41579-020-0433-9.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Khan MAW, Hermann A, et al. The microbiome, cancer, and cancer therapy. Nat Med. 2019;25(3):377–388. doi:10.1038/s41591-019-0377-7.
   PubMed Web of Science ®Google Scholar
• Song M, Chan AT, Sun J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology. 2020; 158(2):322–340. doi:10.1053/j.gastro.2019.06.048.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen WD, Wang YD. The relationship between gut microbiota and inflammatory diseases: the role of macrophages. Front Microbiol. 2020;11:1065. doi:10.3389/fmicb.2020.01065.
   PubMed Web of Science ®Google Scholar
• Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–237. doi:10.1038/s41575-019-0258-z.
   PubMed Web of Science ®Google Scholar
• Allen J, Sears CL. Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development. Genome Med. 2019;11(1):11. doi:10.1186/s13073-019-0621-2.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay I, Dhar R, Pethusamy K, et al. Exploring the role of gut microbiome in colon cancer. Appl Biochem Biotechnol. 2021;193(6):1780–1799. doi:10.1007/s12010-021-03498-9.
   PubMed Web of Science ®Google Scholar
• Schloss PD. Identifying and overcoming threats to reproducibility, replicability, robustness, and generalizability in microbiome research. mBio. 2018; 9(3):10–1128. doi:10.1128/mBio.00525-18.
   Web of Science ®Google Scholar
• Zhang X, Li L, Butcher J, et al. Advancing functional and translational microbiome research using meta-omics approaches. Microbiome. 2019;7(1):154. doi:10.1186/s40168-019-0767-6.
   PubMed Web of Science ®Google Scholar
• Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13(4):260–270. doi:10.1038/nrg3182.
   PubMed Web of Science ®Google Scholar
• Johnson CH, Spilker ME, Goetz L, et al. Metabolite and Microbiome Interplay in Cancer Immunotherapy. Cancer Res. 2016;76(21):6146–6152. doi:10.1158/0008-5472.CAN-16-0309.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–1370. doi:10.1126/science.aar6918.
   PubMed Web of Science ®Google Scholar
• Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 2017;153(6):1621–1633.e6. doi:10.1053/j.gastro.2017.08.022.
   PubMed Web of Science ®Google Scholar
• Yoo JY, Groer M, Dutra SVO, et al. Gut Microbiota and Immune System Interactions. Microorganisms. 2020;8(10):1587. doi:10.3390/microorganisms8101587.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–254. doi:10.3322/caac.21772.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–691. doi:10.1136/gutjnl-2015-310912.
   PubMed Web of Science ®Google Scholar
• Sánchez-Alcoholado L, Ramos-Molina B, Otero A, et al. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers (Basel). 2020;12(6):1406. doi:10.3390/cancers12061406.
   PubMed Web of Science ®Google Scholar
• Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6(1):6528. doi:10.1038/ncomms7528.
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6(1):8727. doi:10.1038/ncomms9727.
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70–78. doi:10.1136/gutjnl-2015-309800.
   PubMed Web of Science ®Google Scholar
• García-González AP, Ritter AD, Shrestha S, et al. Bacterial metabolism affects the C. elegans response to cancer chemotherapeutics. Cell. 2017;169(3):431–441.e8. doi:10.1016/j.cell.2017.03.046.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020;11:615056. doi:10.3389/fimmu.2020.615056.
   PubMed Web of Science ®Google Scholar
• Cipe G, Idiz UO, Firat D, et al. Relationship between intestinal microbiota and colorectal cancer. World J Gastrointest Oncol. 2015;7(10):233–240. doi:10.4251/wjgo.v7.i10.233.
   PubMed Web of Science ®Google Scholar
• Zackular JP, Baxter NT, Iverson KD, et al. The gut microbiome modulates colon tumorigenesis. mBio. 2013;4(6):10–1128. doi:10.1128/mBio.00692-13.
   Web of Science ®Google Scholar
• Chen W, Liu F, Ling Z, et al. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One. 2012;7(6):e39743. doi:10.1371/journal.pone.0039743.
   PubMed Web of Science ®Google Scholar
• Saffarian A, Mulet C, Regnault B, et al. Crypt- and Mucosa-associated core microbiotas in humans and their alteration in colon cancer patients. mBio. 2019;10(4):10–1128. doi:10.1128/mBio.01315-19.
   Web of Science ®Google Scholar
• Coker OO, Nakatsu G, Dai RZ, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;68(4):654–662. doi:10.1136/gutjnl-2018-317178.
   PubMed Web of Science ®Google Scholar
• Dzutsev A, Goldszmid RS, Viaud S, et al. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol. 2015;45(1):17–31. doi:10.1002/eji.201444972.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–215. doi:10.1016/j.chom.2013.07.007.
   PubMed Web of Science ®Google Scholar
• Wang T, Cai G, Qiu Y, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. Isme J. 2012;6(2):320–329. doi:10.1038/ismej.2011.109.
   PubMed Web of Science ®Google Scholar
• Viljoen KS, Dakshinamurthy A, Goldberg P, et al. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One. 2015;10(3):e0119462. doi:10.1371/journal.pone.0119462.
   PubMed Web of Science ®Google Scholar
• Chen D, Wu J, Jin D, et al. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019;145(8):2021–2031. doi:10.1002/ijc.32003.
   PubMed Web of Science ®Google Scholar
• Sánchez B, Delgado S, Blanco-Míguez A, et al. Probiotics, gut microbiota, and their influence on host health and disease. Mol Nutr Food Res. 2017;61(1):1600240. doi:10.1002/mnfr.201600240.
   Web of Science ®Google Scholar
• Raman M, Ambalam P, Kondepudi KK, et al. Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer. Gut Microbes. 2013;4(3):181–192. doi:10.4161/gmic.23919.
   PubMed Web of Science ®Google Scholar
• Heydari Z, Rahaie M, Alizadeh AM, et al. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of microRNAs 135b, 26b, 18a and 155, and their involving genes in mice colon cancer. Probiotics Antimicrob Proteins. 2019;11(4):1155–1162. doi:10.1007/s12602-018-9478-8.
   PubMed Web of Science ®Google Scholar
• Chang C-J, Lin T-L, Tsai Y-L, et al. Next generation probiotics in disease amelioration. J Food Drug Anal. 2019;27(3):615–622. doi:10.1016/j.jfda.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ma R, Liu F, et al. Modulation of gut microbiota: a novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy. Front Immunol. 2018;9:374. doi:10.3389/fimmu.2018.00374.
   PubMed Web of Science ®Google Scholar
• Boesmans L, Valles-Colomer M, Wang J, et al. Butyrate producers as potential next-generation probiotics: safety assessment of the administration of Butyricicoccus pullicaecorum to healthy volunteers. Msystems. 2018;3(6):10–1128. /msystems. 00094-18. doi:10.1128/mSystems.00094-18.
   Web of Science ®Google Scholar
• Chang K, Wei Z, Cao H. A gut butyrate‑producing bacterium Butyricicoccus pullicaecorum regulates short‑chain fatty acid transporter and receptor to reduce the progression of 1, 2‑dimethylhydrazine‑associated colorectal cancer. Oncol Lett. 2020;20(4):1–1. doi:10.3892/ol.2020.11941.
   PubMedGoogle Scholar
• Zaiss MM, Jones RM, Schett G, et al. The gut-bone axis: how bacterial metabolites bridge the distance. J Clin Invest. 2019;129(8):3018–3028. doi:10.1172/JCI128521.
   PubMed Web of Science ®Google Scholar
• Roller M, Femia AP, Caderni G, et al. Intestinal immunity of rats with colon cancer is modulated by oligofructose-enriched inulin combined with Lactobacillus rhamnosus and Bifidobacterium lactis. Br J Nutr. 2004;92(6):931–938. doi:10.1079/bjn20041289.
   PubMed Web of Science ®Google Scholar
• Bruno-Barcena JM, Azcarate-Peril MA. Galacto-oligosaccharides and colorectal cancer: Feeding our intestinal probiome. J Funct Foods. 2015;12:92–108. doi:10.1016/j.jff.2014.10.029.
   PubMed Web of Science ®Google Scholar
• Wegh CA, Geerlings SY, Knol J, et al. Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci. 2019;20(19):4673. doi:10.3390/ijms20194673.
   PubMed Web of Science ®Google Scholar
• Nataraj BH, Ali SA, Behare PV, et al. Postbiotics-parabiotics: the new horizons in microbial biotherapy and functional foods. Microb Cell Fact. 2020;19(1):168. doi:10.1186/s12934-020-01426-w.
   PubMed Web of Science ®Google Scholar
• An BC, Ryu Y, Yoon Y-S, et al. Colorectal cancer therapy using a Pediococcus pentosaceus SL4 drug delivery system secreting lactic acid bacteria-derived protein p8. Mol Cells. 2019;42(11):755.
   PubMed Web of Science ®Google Scholar
• Konishi H, Fujiya M, Tanaka H, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016;7(1):12365. doi:10.1038/ncomms12365.
   PubMedGoogle Scholar
• Iwama T, Fujiya M, Konishi H, et al. Bacteria-derived ferrichrome inhibits tumor progression in sporadic colorectal neoplasms and colitis-associated cancer. Cancer Cell Int. 2021;21(1):21. doi:10.1186/s12935-020-01723-9.
   PubMed Web of Science ®Google Scholar
• Thirabunyanon M, Hongwittayakorn P. Potential probiotic lactic acid bacteria of human origin induce antiproliferation of colon cancer cells via synergic actions in adhesion to cancer cells and short-chain fatty acid bioproduction. Appl Biochem Biotechnol. 2013;169(2):511–525. doi:10.1007/s12010-012-9995-y.
   PubMed Web of Science ®Google Scholar
• Sharma M, Shukla G. Administration of metabiotics extracted from probiotic Lactobacillus rhamnosus MD 14 inhibit experimental colorectal carcinogenesis by targeting Wnt/β-catenin pathway. Front Oncol. 2020;10:746. doi:10.3389/fonc.2020.00746.
   PubMed Web of Science ®Google Scholar
• Norouzi Z, Salimi A, Halabian R, et al. Nisin, a potent bacteriocin and anti-bacterial peptide, attenuates expression of metastatic genes in colorectal cancer cell lines. Microb Pathog. 2018;123:183–189. doi:10.1016/j.micpath.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Patterson E, Cryan JF, Fitzgerald GF, et al. Gut microbiota, the pharmabiotics they produce and host health. Proc Nutr Soc. 2014;73(4):477–489. doi:10.1017/S0029665114001426.
   PubMed Web of Science ®Google Scholar
• Appunni S, Rubens M, Ramamoorthy V, et al. Emerging evidence on the effects of dietary factors on the gut microbiome in colorectal cancer [Review]. Front Nutr. 2021;8:718389. doi:10.3389/fnut.2021.718389.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013;35(2):229–244. doi:10.1007/s00281-012-0352-6.
   PubMed Web of Science ®Google Scholar
• Francescone R, Hou V, Grivennikov SI. Microbiome, inflammation, and cancer. Cancer J. 2014;20(3):181–189. doi:10.1097/PPO.0000000000000048.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Narisawa T, Wright P, et al. Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res. 1975;35(2):287–290.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Narisawa T, Weisburger JH. Colon carcinogenesis in germ-free rats with intrarectal 1,2-dimethylhydrazine and subcutaneous azoxymethane. Cancer Research. 1976;36(8):2874–2876.
   PubMed Web of Science ®Google Scholar
• Son JS, Khair S, Pettet DW, 3rd, et al. Altered interactions between the gut microbiome and colonic mucosa precede polyposis in APCMin/+ Mice. PLoS One. 2015;10(6):e0127985. doi:10.1371/journal.pone.0127985.
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306. doi:10.1101/gr.126516.111.
   PubMed Web of Science ®Google Scholar
• Ye X, Wang R, Bhattacharya R, et al. Fusobacterium nucleatum subspecies animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. Cancer Prev Res (Phila). 2017;10(7):398–409. doi:10.1158/1940-6207.CAPR-16-0178.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; Aug 1414(2):195–206. doi:10.1016/j.chom.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Li L, Li X, Zhong W, et al. Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apc(min/+) mice. EBioMedicine. 2019;48:301–315. doi:10.1016/j.ebiom.2019.09.021.
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–1980. doi:10.1136/gutjnl-2015-310101.
   PubMed Web of Science ®Google Scholar
• Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7(29):46158–46172. doi:10.18632/oncotarget.10064.
   PubMedGoogle Scholar
• Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015;1(5):653–661. doi:10.1001/jamaoncol.2015.1377.
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355. doi:10.1016/j.immuni.2015.01.010.
   PubMed Web of Science ®Google Scholar
• Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017; May17(5):271–285. doi:10.1038/nrc.2017.13.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084. doi:10.1126/science.aad1329.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–1089. doi:10.1126/science.aac4255.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. doi:10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359(6371):104–108. doi:10.1126/science.aao3290.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–97. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Hayase E, Jenq RR. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Med. 2021;13(1):107. doi:10.1186/s13073-021-00923-w.
   PubMed Web of Science ®Google Scholar
• Krasteva N, Georgieva M. Promising therapeutic strategies for colorectal cancer treatment based on nanomaterials. Pharmaceutics. 2022;14(6):1213. doi:10.3390/pharmaceutics14061213.
   PubMed Web of Science ®Google Scholar
• Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409–421. doi:10.1111/apt.12878.
   PubMed Web of Science ®Google Scholar
• Nam YD, Kim HJ, Seo JG, et al. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One. 2013;8(12):e82659. doi:10.1371/journal.pone.0082659.
   PubMed Web of Science ®Google Scholar
• Al-Qadami G, Van Sebille Y, Le H, et al. Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. Expert Rev Gastroenterol Hepatol. 2019;13(5):485–496. doi:10.1080/17474124.2019.1595586.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970. doi:10.1126/science.1240527.
   PubMed Web of Science ®Google Scholar
• Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381–1390. doi:10.1007/s10096-014-2081-3.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–563.e16. doi:10.1016/j.cell.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Pan HW, Du LT, Li W, et al. Biodiversity and richness shifts of mucosa-associated gut microbiota with progression of colorectal cancer. Res Microbiol. 2020;171(3–4):107–114. doi:10.1016/j.resmic.2020.01.001.
   PubMed Web of Science ®Google Scholar
• Hibberd AA, Lyra A, Ouwehand AC, et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol. 2017;4(1):e000145. doi:10.1136/bmjgast-2017-000145.
   PubMed Web of Science ®Google Scholar
• Lee HA, Kim H, Lee KW, et al. Dead nano-sized lactobacillus plantarum inhibits azoxymethane/dextran sulfate sodium-induced colon cancer in Balb/c mice. J Med Food. 2015;18(12):1400–1405. doi:10.1089/jmf.2015.3577.
   PubMed Web of Science ®Google Scholar
• Talero E, Bolivar S, Ávila-Román J, et al. Inhibition of chronic ulcerative colitis-associated adenocarcinoma development in mice by VSL#3. Inflamm Bowel Dis. 2015;21(5):1027–1037. doi:10.1097/MIB.0000000000000346.
   PubMed Web of Science ®Google Scholar
• Gamallat Y, Meyiah A, Kuugbee ED, et al. Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed Pharmacother. 2016;83:536–541. doi:10.1016/j.biopha.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Arrastia M, Martinez-Ortigosa A, Rueda-Ruzafa L, et al. Probiotic supplements on oncology patients’ treatment-related side effects: a systematic review of randomized controlled trials. Int J Environ Res Public Health. 2021;18(8):4265. doi:10.3390/ijerph18084265.
   PubMed Web of Science ®Google Scholar
• Veiga P, Suez J, Derrien M, et al. Moving from probiotics to precision probiotics. Nat Microbiol. 2020;5(7):878–880. doi:10.1038/s41564-020-0721-1.
   PubMed Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013;29(1):79–84. doi:10.1097/MOG.0b013e32835a4b3e.
   PubMed Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415. doi:10.1056/NEJMoa1205037.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228. doi:10.1016/S0140-6736(17)30182-4.
   PubMed Web of Science ®Google Scholar
• Rosshart SP, Vassallo BG, Angeletti D, et al. Wild mouse gut microbiota promotes host fitness and improves disease resistance. Cell. 2017;171(5):1015–1028.e13. doi:10.1016/j.cell.2017.09.016.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804–1808. doi:10.1038/s41591-018-0238-9.
   PubMed Web of Science ®Google Scholar
• Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595–602. doi:10.1126/science.abf3363.
   PubMed Web of Science ®Google Scholar
• Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602–609. doi:10.1126/science.abb5920.
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Boleij A, Marchesi JR, et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–582. doi:10.1038/nrmicro2819.
   PubMed Web of Science ®Google Scholar
• Sinha R, Ahsan H, Blaser M, et al. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017. Microbiome. 2018;6(1):210. doi:10.1186/s40168-018-0596-z.
   PubMedGoogle Scholar
• Katti A, Diaz BJ, Caragine CM, et al. CRISPR in cancer biology and therapy. Nat Rev Cancer. 2022;22(5):259–279. doi:10.1038/s41568-022-00441-w.
   PubMed Web of Science ®Google Scholar
• Mehmood A, Ali W, Din ZU, et al. Clustered regularly interspaced short palindromic repeats as an advanced treatment for Parkinson’s disease. Brain Behav. 2021;11(8):e2280. doi:10.1002/brb3.2280.
   PubMed Web of Science ®Google Scholar
• Faïs T, Delmas J, Cougnoux A, et al. Targeting colorectal cancer-associated bacteria: A new area of research for personalized treatments. Gut Microbes. 2016;7(4):329–333. doi:10.1080/19490976.2016.1155020.
   PubMed Web of Science ®Google Scholar